Neumora Therapeutics, Inc. (NMRA) - 10-K Summary
Business Context and Reporting Period
Company: Neumora Therapeutics, Inc.
Filing Type: Annual Report on Form 10-K
Period Ended: December 31, 2024
Business Overview: Neumora is a clinical-stage biopharmaceutical company focused on developing novel therapies for neuropsychiatric disorders and neurodegenerative diseases using a "precision neuroscience" approach. The company has no approved products and has not generated any product revenue.
Key Pipeline Assets:
- Navacaprant (NMRA-140): A kappa opioid receptor (KOR) antagonist for Major Depressive Disorder (MDD). Currently in pivotal Phase 3 (KOASTAL program). Topline data for KOASTAL-3 expected Q1 2026; KOASTAL-2 expected Q2 2026.
- NMRA-511: A vasopressin 1a receptor (V1aR) antagonist for agitation associated with Alzheimer's disease. Advancing Phase 1b signal-seeking study; data expected by end of 2025.
- M4 PAM Franchise: Multiple compounds targeting the M4 receptor for schizophrenia and other disorders. Next candidate expected to enter clinic mid-2025.
- Preclinical Programs: Includes NMRA-NMDA (schizophrenia), NMRA-CK1δ (ALS), NMRA-NLRP3 (Parkinson's), and NMRA-GCase (Parkinson's).
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(243.8) million | $(235.9) million | $(7.9) million |
| Operating Expenses | $263.5 million | $252.1 million | $11.4 million |
| Research & Development (R&D) | $200.9 million | $142.7 million | $58.2 million |
| General & Administrative (G&A) | $62.5 million | $45.5 million | $17.1 million |
| Acquired IPR&D Expenses | $0 | $63.9 million | $(63.9) million |
| Cash, Cash Equivalents & Marketable Securities | $307.6 million | $452.0 million | $(144.4) million |
| Accumulated Deficit | $(947.2) million | $(703.4) million | N/A |
Note: Figures in millions unless otherwise noted. No debt is reported on the balance sheet.
Material Changes vs. Prior Period
- R&D Expense Increase: R&D expenses increased by 41% ($58.2 million) primarily due to the advancement of Phase 3 and Phase 2 clinical trials for navacaprant. Direct external program expenses for navacaprant rose from $37.9 million in 2023 to $105.4 million in 2024.
- Elimination of IPR&D Charges: In 2023, the company recorded $63.9 million in acquired in-process research and development (IPR&D) expenses related to milestone achievements (BlackThorn and Vanderbilt). No such charges were recorded in 2024.
- Cash Position: Cash and marketable securities decreased by approximately $144 million, driven by operating cash outflows of $182.9 million and investing activities (net purchases of marketable securities) of $70.6 million.
- Stock-Based Compensation: Total stock-based compensation increased significantly to $40.0 million in 2024 from $17.2 million in 2023, driven by stock modification expenses and increased value of awards.
Guidance, Outlook, and Risks
Outlook and Milestones:
- Navacaprant: Following the KOASTAL-1 study results in January 2025 (which did not meet primary endpoints), the company is adjusting site selection and medical monitoring for the remaining KOASTAL-2 and KOASTAL-3 studies. Topline data is expected in 2026.
- NMRA-511: Phase 1b data expected by end of 2025.
- M4 PAM: Next candidate expected to enter clinic mid-2025.
Liquidity: As of December 31, 2024, the company had $307.6 million in cash and marketable securities. Management believes this is sufficient to fund operations for at least the next 12 months. The company expects to incur significant losses for the foreseeable future and will require additional funding to complete development and commercialization.
Key Risks and Contingencies:
- Clinical Trial Failure: The failure of the KOASTAL-1 primary endpoint highlights the high risk of clinical development in neuroscience. Future trials may also fail.
- Regulatory Holds: The Phase 1 trial for NMRA-266 (M4 PAM) was placed on clinical hold by the FDA in April 2024 due to convulsions in nonclinical rabbit studies. Resolution is not guaranteed.
- Contingent Consideration: The company has significant potential future payment obligations (milestones and royalties) to BlackThorn stockholders, Amgen, TSRI, and Vanderbilt, totaling hundreds of millions of dollars if development and commercial milestones are met.
- Legal Proceedings: A putative securities class action lawsuit was filed in February 2025 alleging violations related to the IPO and navacaprant prospects. The company intends to dismiss.
Investor Verification Checklist
- KOASTAL-1 Analysis: Verify the specific adjustments being made to the KOASTAL-2 and KOASTAL-3 protocols following the KOASTAL-1 failure and the rationale for the observed sex-based subgroup trends.
- NMRA-266 Clinical Hold: Monitor communications with the FDA regarding the resolution of the clinical hold on the NMRA-266 program and the impact on the M4 PAM timeline.
- Cash Burn Rate: Assess the sustainability of the $307.6 million cash balance given the increased R&D spend and the need for future capital raises.
- Contingent Liabilities: Review the specific terms of the BlackThorn, Amgen, and Vanderbilt agreements to understand the magnitude of potential future cash or equity dilution.
- Legal Status: Track the progress of the February 2025 securities class action lawsuit.